Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.36 |
| ▸ | USP8 | P40818 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31673244 | 0.78 | EGLN2 (0.34) | EGLN2HSD11B1 | |
| SCHEMBL701812 | 0.77 | NOS3 (0.44) | EGLN2HSD11B1NQO1SOS2 | |
| SCHEMBL28031858 | 0.77 | EGLN2 (0.39) | EGLN2NQO1SOS2USP8USP7 | |
| SCHEMBL11942290 | 0.77 | EGLN2 (0.39) | EGLN2NQO1USP8USP7CYP11B1 | |
| SCHEMBL21928096 | 0.76 | EGLN2 (0.40) | EGLN2NQO1SOS2CYP11B1CYP11B2 | |
| SCHEMBL24141635 | 0.74 | EGLN2 (0.39) | EGLN2NQO1SOS2 | |
| SCHEMBL1973272 | 0.74 | SOS2 (0.48) | EGLN2NQO1SOS2 | |
| SCHEMBL31036143 | 0.74 | SOS2 (0.44) | EGLN2NQO1SOS2METCYP11B1 | |
| SCHEMBL1449669 | 0.74 | EGLN2 (0.43) | EGLN2NQO1SOS2 | |
| SCHEMBL149575 | 0.74 | EGLN2 (0.39) | EGLN2NQO1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720065-A1 | PRMT5 INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720041-A2 | N-(1H-INDOL-2-YL)METHYL)-4-ETHYNYL-PICOLINAMIDE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Allorion Therapeutics Inc (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc | 2025-01-23 | — | — | US | disclosed |
| WO-2024245412-A1 | PRMT5 INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024240241-A2 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc (US) | 2024-11-28 | — | — | WO | disclosed |
| CN-118251390-A | Heteroaryl linked analogs as MGLU5 negative allosteric modulators and methods of making and using the same | 范德比尔特大学 | 2024-06-25 | — | — | CN | disclosed |
| US-9540388-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-10 | — | — | US | disclosed |
| US-20160039836-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| EP-2970287-A1 | P2X7 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152621-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-8114989-B2 | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| CN-101238116-A | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | CN | disclosed |
| EP-1899323-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | EGLN2 1148/4885HSD11B1 4310/4885NQO1 1474/4885 |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | EGLN2 1186/4885HSD11B1 3404/4885NQO1 1600/4885 |
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | EGLN2 3961/4885HSD11B1 381/4885NQO1 1924/4885 |
| US-20160039836-A1 | P2X7 MODULATORS | P2RX1, P2RX7, P2RX5 | EGLN2 1066/4885HSD11B1 1991/4885NQO1 260/4885 |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ABL1, FLT3, ERBB2 | EGLN2 1186/4885HSD11B1 3404/4885NQO1 1600/4885 |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB3, ERBB2 | EGLN2 3566/4885HSD11B1 4699/4885NQO1 3915/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | EGLN2 1148/4885HSD11B1 4310/4885NQO1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.